Markedsføringsindehaveren skal informere den Europæiske Kommission om markedsføringsplanerne for lægemidlet, der godkendes under denne procedure.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.